Navigation Links
CardioDynamics Provides 2007 Shareholder Meeting Update
Date:8/19/2007

Strong Shareholder Support for Vermed Sale

SAN DIEGO, Aug. 16 /PRNewswire-FirstCall/ -- CardioDynamics International Corporation (Nasdaq: CDIC), the innovator and leader of impedance cardiography (ICG) technology, today announced that the shareholder vote for the sale of Vermed is progressing well with over 50% of the necessary shareholder votes (approximately 27% of outstanding shares) already cast in favor of the Vermed sale. The ratio of votes received is running in excess of 90% for, and less than 10% against, the sale of Vermed. The annual shareholder meeting is scheduled for August 28, 2007, at 9:00 am, P.T., at the Company's headquarters. If a shareholder has not received their proxy materials or needs a replacement, they can contact Advantage Proxy toll free at (800) 238-3410, extension 34.

Michael K. Perry, CardioDynamics' Chief Executive Officer, stated, "In addition to the votes already received, I have spoken with a number of large shareholders who have indicated a yes vote, including Dr. Herbert Wertheim, who owns approximately 9% of the company's outstanding shares. I am confident we will get the required votes, but additional shareholder support is still needed."

Dr. Herbert Wertheim, CardioDynamics' largest individual shareholder, added, "After review of the proxy, further research and discussions with management, I support the sale of Vermed, which will allow focus and important investment into CardioDynamics core technology. ICG is a cost-effective, revolutionary technology that assists in predicting future heart failure events and is invaluable in the treatment of cardiovascular disease, from which one out of every two Americans will eventually die. CardioDynamics has a seasoned management team dedicated to making a difference in healthcare through their long-term commitment and focus on evidence-based medical studies demonstrating ICG's clinical and cost-effectiveness benefits. Historically, I have invested in undervalued companies with innovative technologies and strong management teams, and I believe CardioDynamics fits these criteria exceptionally well."

Perry concluded, "The Vermed team has secured the financing for the purchase and is awaiting our shareholder approval. Both organizations are looking forward to completing this transaction and maintaining a long term, mutually beneficial relationship."

About CardioDynamics:

CardioDynamics, the ICG Company, is the innovator and leader of an important medical technology called impedance cardiography. The Company develops, manufactures and markets noninvasive diagnostic and monitoring technologies and medical device electrodes. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare and Philips Medical Systems. For additional information, please refer to the company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for historical and factual information contained herein, this press release contains forward-looking statements, including the Company's ability to obtain the votes necessary to complete the sale of Vermed and the expected closing of the transaction, the accuracy of which is necessarily subject to uncertainties and risks including the Company's primary dependence on the BioZ product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2006 Form 10-K and proxy statement filed with the SEC on July 20, 2007. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics International Corporation

Copyright©2007 PR Newswire.

Related biology technology :

1. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
2. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
3. State provides $200K for Necedah ethanol plant
4. Madison firm provides $200K in capital to tech companies
5. Mirus provides low-cost way to modify genes
6. MDC provides venture funding for tech companies
7. IT Fusion SOS provides outsourced IT aid to small businesses
8. BIO provides forum for Wisconsin to showcase strengths
9. Imago provides atomic probe to Australian lab
10. Online Kiosks provides a new way to send a message
11. Small Tree provides Apple drivers for Intels new 10-gigabit Ethernet cards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Four US Biotech equities have been ... are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. ... and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ). ... are growing more bullish on the sector as a ... cash held overseas for tax reason by large US ...
(Date:2/27/2017)... ... 27, 2017 , ... The Catalyst Midwest premix manufacturing facility has ... premix services and private label organic services. , The first organic product is Organic ... operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has received ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology ... the National Institute of Mental Health (NIMH) for the further advancement of the company’s ... technology and is expected to deliver therapeutic levels of olanzapine for a period ...
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/3/2017)... WASHINGTON , Feb. 3, 2017 A ... Identity Strategy Partners, LLP (IdSP) . Designed to ... in the complex identity market, founding partners Mark ... nearly 35 combined years just in identity expertise that ... tank and non-profit leadership. The Crego-Kephart combined expertise has ...
Breaking Biology News(10 mins):